October 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Hair loss significantly affects emotional and social well-being.
October 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Hair loss significantly affects emotional and social well-being.
September 2025 in “Journal of the Pakistan Medical Association” Tofacitinib effectively and safely promotes hair regrowth in alopecia patients.
September 2025 in “Turkish Journal of Dermatology” Oxidative stress may play a role in alopecia areata, but depression and suicide risk are similar to healthy peers.
September 2025 in “Tạp chí Da liễu học Việt Nam” 2.5 mg/mL TAC is as effective and safe as 5 mg/mL, but 5 mg/mL may improve hair regrowth and density more.
September 2025 in “Journal of the American Academy of Dermatology” Eyebrow and eyelash hair loss in alopecia areata worsens quality of life.
August 2025 in “Zanco Journal of Medical Sciences” Both steroid and vitamin D3 treatments are safe and effective for patchy alopecia areata, with steroids showing slightly better results.
May 2025 in “Journal of the Egyptian Womenʼs Dermatologic Society” Vitamin D3 is a safe and effective alternative to steroids for treating alopecia areata, with fewer side effects.
March 2025 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.
March 2025 in “Dermatologic Surgery” Fractional radiofrequency microneedling is as effective and safe as intralesional steroids for treating patchy alopecia areata, with fewer side effects.
January 2025 in “Dermatologic Therapy” Alopecia areata may be linked to higher heart disease risk.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Disease-specific tools better assess quality of life in alopecia areata patients.
November 2024 in “Journal of the Philippine Dermatological Society” Combining methotrexate and corticosteroids can effectively regrow hair in severe alopecia areata.
Mesenchymal Stem Cell Conditioned Media can significantly regrow hair in alopecia areata patients.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
April 2024 in “Research Square” Children with alopecia areata often experience more anxiety and depression, linked to neglectful family dynamics.
April 2024 in “Skin research and technology” Minoxidil with triamcinolone acetonide is more effective for mild alopecia areata when injected with microneedles than when applied topically.
March 2024 in “Clinical and experimental dermatology” Topical corticosteroids may be a safe and effective treatment for severe alopecia areata in children.
September 2023 in “PubMed” Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
December 2022 in “International Journal of Women's Dermatology” The Sinclair Shedding Scale is effective for diagnosing Alopecia Areata Incognita and monitoring treatment success.
July 2022 in “المجلة العراقية للصيدلة” Azelaic acid 20% cream works well for treating scalp alopecia areata and can be an alternative to clobetasol ointment.
July 2022 in “The Egyptian Journal of Hospital Medicine” Targeting IL-15 may help treat Alopecia Areata.
January 2021 in “International journal of basic and clinical pharmacology” Hydroxychloroquine is less effective than betamethasone oral mini pulse therapy for treating alopecia areata.
September 2020 in “Benha Journal of Applied Sciences” Higher IL-19 levels are linked to more severe Alopecia Areata.
July 2013 in “Our Dermatology Online” Minoxidil 2% is more effective than tacrolimus 0.1% for hair regrowth in mild to moderate patchy hair loss, and combining both might give better results.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
January 2026 in “International Journal of Dermatology” The new tool helps measure the impact of alopecia areata on children's quality of life.
November 2025 in “Figshare” Baseline severity, disease activity, and relapse history are key to predicting response and recurrence in alopecia areata.
November 2025 in “Journal of Investigative Dermatology” Combination therapy, including JAK inhibitors, effectively regrows hair and reduces severity in Black children with stubborn Alopecia Areata.